Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 5/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.42 |
| ▸ | FAAH | O00519 | 3/20 | 0.42 |
| ▸ | CDC25A | P30304 | 3/20 | 0.37 |
| ▸ | CES1 | P23141 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.35 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 3/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24017084 | 0.97 | MGLL (0.41) | MGLLPTGS1PTGS2FAAHCDC25A | |
| SCHEMBL24017089 | 0.83 | PTGS1 (0.47) | MGLLPTGS1PTGS2FAAHCDC25A | |
| SCHEMBL20964322 | 0.83 | STAT3 (0.47) | MGLLPTGS1PTGS2FAAHCDC25A | |
| SCHEMBL20964344 | 0.81 | PTGS1 (0.45) | MGLLPTGS1PTGS2FAAHCDC25A | |
| SCHEMBL26198042 | 0.80 | CDC25A (0.46) | MGLLPTGS1PTGS2FAAHCDC25A | |
| SCHEMBL22605887 | 0.78 | MEN1 (0.51) | CDC25ACES1ALDH1A1FGFR1KDR | |
| SCHEMBL24603646 | 0.77 | MEN1 (0.33) | ALDH1A1 | |
| SCHEMBL24603682 | 0.75 | TDP1 (0.47) | CDC25ACES1ALDH1A1 | |
| SCHEMBL20964336 | 0.73 | PDE5A (0.38) | MGLLPTGS1PTGS2FAAHCDC25A | |
| SCHEMBL27071534 | 0.73 | CYP1B1 (0.47) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025901-A1 | METHOD FOR PRODUCING CYCLIC IMIDE COMPOUND, COMPOSITION, AND COMPOUND | FUJIFILM CORPORATION (JP) | 2024-01-25 | — | — | US | disclosed |
| US-20240025901-A1 | METHOD FOR PRODUCING CYCLIC IMIDE COMPOUND, COMPOSITION, AND COMPOUND | FUJIFILM CORPORATION (JP) | 2024-01-25 | — | — | US | disclosed |
| US-11785845-B2 | Composition | FUJIFILM CORPORATION (JP) | 2023-10-10 | — | — | US | disclosed |
| US-20220213104-A1 | METHOD FOR PRODUCING CYCLIC IMIDE COMPOUND, COMPOSITION, AND COMPOUND | FUJIFILM CORPORATION (JP) | 2022-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025901-A1 | METHOD FOR PRODUCING CYCLIC IMIDE COMPOUND, COMPOSITION, AND COMPOUND | INF2, NISCH, ITPA | MGLL 3660/4885PTGS1 1043/4885PTGS2 605/4885 |
| US-11785845-B2 | Composition | ADH1A, ADH1C, SLC19A2 | MGLL 1276/4885PTGS1 795/4885PTGS2 1829/4885 |
| US-20220213104-A1 | METHOD FOR PRODUCING CYCLIC IMIDE COMPOUND, COMPOSITION, AND COMPOUND | INF2, NISCH, ITPA | MGLL 3660/4885PTGS1 1043/4885PTGS2 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.